Results 21 to 30 of about 606,260 (153)

The role of coagulation hemostasis for development of early-onset preeclampsia in low-risk patients

Акушерство, гинекология и репродукция, 2022
Aim: to determine a role of specific parameters of coagulation hemostasis for development of severe early-onset preeclampsia (еPE) in low-risk patients.Materials and Methods.
M. G. Nikolaeva, K. V. Shchekleina, A. P. Momot, V. Yu. Terekhina, E. V. Grigorieva   +4 more
doaj   +1 more source

Research progress on clinical application of anti-tissue factor pathway inhibitor in hemophilia [PDF]

Zhenduanxue lilun yu shijian
In recent years， to address the unmet needs in hemophilia treatment， significant research has led to unprecedented advances in pharmacotherapy， including the development of several innovative mechanism-based therapies that restore hemostatic balance by ...
XIAO Jianwen, YI Weijia
doaj   +1 more source

Plasma Tissue Factor Pathway Inhibitor Levels in Angiographically Defined Coronary Artery Disease Among Saudis

Oman Medical Journal, 2013
Objectives: This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic
Syed Shahid Habib
doaj   +1 more source

Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis

Arthritis Research & Therapy, 2019
Objective This study evaluates the utility of urinary pro-thrombotic molecules such as tissue factor (TF), anti-thrombotic molecules such as tissue factor pathway inhibitor (TFPI), and fibrinolytic molecules such as plasmin and d-dimer as biomarkers of ...
Ling Qin, Samantha Stanley, Huihua Ding, Ting Zhang, Van Thi Thanh Truong, Teja Celhar, Anna-Marie Fairhurst, Claudia Pedroza, Michelle Petri, Ramesh Saxena, Chandra Mohan   +10 more
doaj   +1 more source

Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction

Platelets, 2020
The aim of the study was to evaluate diurnal changes of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) concentrations in relation to on-treatment platelet reactivity.
Joanna Boinska, Marek Koziński, Michał Kasprzak, Katarzyna Ziołkowska, Inga Dziembowska, Michał Ziołkowski, Jacek Kubica, Danuta Rość   +7 more
doaj   +1 more source

Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis

Advanced Biomedical Research, 2015
Background: Decreased concentration of tissue factor pathway inhibitor (TFPI) is a risk factor for development of deep venous thrombosis and coronary heart disease, but there is no evidence for the relationship between TFPI and cerebral venous and sinus ...
Shaghayegh Haghjooy Javanmard, Tayebeh Shahsavarzadeh, Mohammad Saadatnia   +2 more
doaj   +1 more source

Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity. [PDF]

PLoS ONE, 2012
Islet and hepatocyte transplantation are associated with tissue factor-dependent activation of coagulation which elicits instant blood mediated inflammatory reaction, thereby contributing to a low rate of engraftment.
Xavier Stephenne, Emanuele Nicastro, Stephane Eeckhoudt, Cedric Hermans, Omar Nyabi, Catherine Lombard, Mustapha Najimi, Etienne Sokal   +7 more
doaj   +1 more source

Biology of tissue factor pathway inhibitor

Blood, 2014
AbstractRecent studies of the anticoagulant activities of the tissue factor (TF) pathway inhibitor (TFPI) isoforms, TFPIα and TFPIβ, have provided new insight into the biochemical and physiological mechanisms that underlie bleeding and clotting disorders. TFPIα and TFPIβ have tissue-specific expression patterns and anticoagulant activities.
Wood, J., Ellery, Paul, Maroney, S., Mast, A.   +3 more
openaire   +4 more sources

Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII

Haematologica, 2010
Background Heparanase is an endo-β-D-glucuronidase dominantly involved in tumor metastasis and angiogenesis. Recently, we demonstrated that heparanase is involved in the regulation of the hemostatic system.
Yona Nadir, Benjamin Brenner, Liat Fux, Itay Shafat, Judith Attias, Israel Vlodavsky   +5 more
doaj   +1 more source

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state

Blood Advances, 2017
: Activated factor V (FVa) and factor X (FXa) form prothrombinase, which converts prothrombin to thrombin. The α isoform of tissue factor pathway inhibitor (TFPI) dampens early procoagulant events, partly by interacting with FV.
Jeremy P. Wood, Lisa M. Baumann Kreuziger, Paul E.R. Ellery, Susan A. Maroney, Alan E. Mast   +4 more
doaj   +1 more source